{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:30:43Z","timestamp":1781591443784,"version":"3.54.5"},"reference-count":279,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011962","name":"Research Center for Infectious Diseases and Tropical Medicine, Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011962","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119284","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:08:43Z","timestamp":1776164923000},"page":"119284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting human oncogenic viruses with CRISPR\/Cas: New therapeutic opportunities and challenges"],"prefix":"10.1016","volume":"198","author":[{"given":"Maryam Pourdehghan","family":"Jigheh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Zenderuh","family":"Ravanlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahya Zarei","family":"Shahrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aria","family":"Mohabbat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein Bannazadeh","family":"Baghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119284_bib1","series-title":"Viruses and human cancer: from basic science to clinical prevention","first-page":"1","article-title":"An introduction to virus infections and human cancer","author":"Schiller","year":"2020"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004564","article-title":"Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis","volume":"10","author":"Chaudhary","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119284_bib3","article-title":"The Role of DNA viruses in human cancer","volume":"22","author":"Ghoreshi","year":"2023","journal-title":"Cancer Inform."},{"key":"10.1016\/j.biopha.2026.119284_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1333812","article-title":"Viral oncogenes, viruses, and cancer: a third-generation sequencing perspective on viral integration into the human genome","volume":"13","author":"Ye","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","article-title":"Viral oncogenesis in cancer: from mechanisms to therapeutics","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40001-023-01014-9","article-title":"siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy","volume":"28","author":"Shiri Aghbash","year":"2023","journal-title":"Eur. J. Med Res"},{"key":"10.1016\/j.biopha.2026.119284_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-virology-020420-014025","article-title":"Herpesvirus epigenetic reprogramming and oncogenesis","volume":"7","author":"Pei","year":"2020","journal-title":"Annu. Rev. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.48022\/mbl.2303.03006","article-title":"Pathogenesis of oncoviruses: a systemic review","volume":"51","author":"Abedien","year":"2023","journal-title":"Microbiol. Biotechnol. Lett."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers13020305","article-title":"Oncogenic effects of HIV-1 proteins, mechanisms behind","volume":"13","author":"Isaguliants","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.biopha.2026.119284_bib10","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1021\/acs.molpharmaceut.2c01080","article-title":"Recent updates on viral oncogenesis: available preventive and therapeutic entities","volume":"20","author":"Chowdhary","year":"2023","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/cncr.30588","article-title":"Human papillomavirus in cervical cancer and oropharyngeal cancer: one cause, two diseases","volume":"123","author":"Berman","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/v12020188","article-title":"Reduce and control: a combinatorial strategy for achieving sustained HIV remissions in the absence of antiretroviral therapy","volume":"12","author":"Schwarzer","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/pathogens12010056","article-title":"A landscape of CRISPR\/Cas technique for emerging viral disease diagnostics and therapeutics: progress and prospects","volume":"12","author":"Tripathi","year":"2022","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12033-021-00422-8","article-title":"CRISPR\/Cas-based modifications for therapeutic applications: a review","volume":"64","author":"Bharathkumar","year":"2022","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119284_bib15","article-title":"CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib16","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/v14122654","article-title":"Gene editing technologies to target HBV cccDNA","volume":"14","author":"Martinez","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib17","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.molcel.2014.03.011","article-title":"CRISPR-Cas systems: prokaryotes upgrade to adaptive immunity","volume":"54","author":"Barrangou","year":"2014","journal-title":"Mol. Cell"},{"issue":"6096","key":"10.1016\/j.biopha.2026.119284_bib20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"science"},{"issue":"6213","key":"10.1016\/j.biopha.2026.119284_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119284_bib22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"issue":"6176","key":"10.1016\/j.biopha.2026.119284_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.1247997","article-title":"Structures of Cas9 endonucleases reveal RNA-mediated conformational activation","volume":"343","author":"Jinek","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib24","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1038\/s41467-022-30515-0","article-title":"CRISPR\/Cas9 gRNA activity depends on free energy changes and on the target PAM context","volume":"13","author":"Corsi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119284_bib25","first-page":"1","article-title":"Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects","author":"Cetin","year":"2025","journal-title":"Expert Rev. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00439-018-1953-5","article-title":"Ways of improving precise knock-in by genome-editing technologies","volume":"138","author":"Smirnikhina","year":"2019","journal-title":"Hum. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","article-title":"Repair of DNA double-strand breaks by the nonhomologous end joining pathway","volume":"90","author":"Stinson","year":"2021","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.biopha.2026.119284_bib28","first-page":"1","article-title":"Gene editing and CRISPR-dependent homology-mediated end joining","author":"Ruis","year":"2025","journal-title":"Exp. & Mol. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119284_bib29","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.3390\/ijms23115992","article-title":"Improving homology-directed repair in genome editing experiments by influencing the cell cycle","volume":"23","author":"Smirnikhina","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib30","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.3390\/ijms25052456","article-title":"Current strategies for increasing knock-in efficiency in CRISPR\/Cas9-based approaches","volume":"25","author":"Leal","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14218\/ERHM.2023.00053","article-title":"Cancers Associated with Human Papillomavirus: an overview of prevalence in Iran and the Middle East","volume":"9","author":"Baghi","year":"2024","journal-title":"Explor. Res. Hypothesis Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13027-024-00624-0","article-title":"Prevalence of HPV in anal cancer: exploring the role of infection and inflammation","volume":"19","author":"Ebrahimi","year":"2024","journal-title":"Infect. Agent Cancer"},{"key":"10.1016\/j.biopha.2026.119284_bib33","unstructured":"(CDC) CfDCaP. Human Papillomavirus (HPV) 2024 [Available from: \u3008https:\/\/www.cdc.gov\/hpv\/index.html\u3009."},{"key":"10.1016\/j.biopha.2026.119284_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/ijph.2022.1604621","article-title":"Is it time to genotype beyond HPV16 and HPV18 for cervical cancer screening?","volume":"67","author":"Chua","year":"2022","journal-title":"Int. J. Public Health"},{"key":"10.1016\/j.biopha.2026.119284_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113625","article-title":"The role of immune cells and inflammasomes in Modulating cytokine responses in HPV-Related cervical cancer","volume":"145","author":"Shiri Aghbash","year":"2025","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119284_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25","author":"Doorbar","year":"2015","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2026.119284_bib37","article-title":"Cluster of differentiation frequency on antigen presenting-cells: The next step to cervical cancer prognosis?","volume":"108","author":"Aghbash","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-024-02083-w","article-title":"Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119284_bib39","article-title":"HPV-Specific Antivirals: Disarming Viral Entry and Disruption of Replication","author":"Ravanlo","year":"2025","journal-title":"Microbe"},{"key":"10.1016\/j.biopha.2026.119284_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fcimb.2020.00035","article-title":"The role of promyelocytic leukemia nuclear bodies during HPV infection","volume":"10","author":"Guion","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119284_bib41","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib42","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/v7072802","article-title":"Human papillomaviruses; epithelial tropisms, and the development of neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"issue":"18","key":"10.1016\/j.biopha.2026.119284_bib43","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.3390\/ijms26189214","article-title":"From Viral Infection to Genome Reshaping: The Triggering Role of HPV Integration in Cervical Cancer","volume":"26","author":"Li","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13353-024-00883-y","article-title":"HPV-driven oncogenesis\u2014much more than the E6 and E7 oncoproteins","volume":"66","author":"Janiszewska","year":"2025","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.biopha.2026.119284_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.meegid.2019.04.018","article-title":"The interaction of human papillomaviruses and adeno-associated viruses in suppressive co-infections","volume":"73","author":"Hemmat","year":"2019","journal-title":"Infect. Genet Evol."},{"key":"10.1016\/j.biopha.2026.119284_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s13027-026-00733-y","article-title":"Silencing HPV: the rise of RNA therapeutics in cervical cancer","author":"Khorramabadi","year":"2026","journal-title":"Infect. Agents Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib47","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3390\/biology12050672","article-title":"PI3K\/AKT\/mTOR signaling pathway in HPV-driven head and neck carcinogenesis: therapeutic implications","volume":"12","author":"Aguayo","year":"2023","journal-title":"Biology"},{"issue":"8","key":"10.1016\/j.biopha.2026.119284_bib48","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.3390\/v7082842","article-title":"Regulation of the Wnt\/\u03b2-catenin signaling pathway by human papillomavirus E6 and E7 oncoproteins","volume":"7","author":"Munoz Bello","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib49","first-page":"105","article-title":"Notch signaling and human papillomavirus\u2013associated oral tumorigenesis","author":"Das","year":"2020","journal-title":"Notch Signaling Embryology Cancer Notch Signaling Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.32604\/or.2022.026776","article-title":"The effect of Wnt\/\u03b2-catenin signaling on PD-1\/PDL-1 axis in HPV-related cervical cancer","volume":"30","author":"Aghbash","year":"2022","journal-title":"Oncol. Res"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/v16050680","article-title":"Human papillomavirus and associated cancers: a review","volume":"16","author":"Jensen","year":"2024","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ijgc-2020-001285","article-title":"World Health Organization call for action to eliminate cervical cancer globally","volume":"30","author":"Gultekin","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2026.119284_bib53","unstructured":"Organization W.H. Cervical cancer 2024 [Available from: URL h\u3008ttps:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer\u3009."},{"key":"10.1016\/j.biopha.2026.119284_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.904790","article-title":"Monoclonal antibodies in cervical malignancy-related HPV","volume":"12","author":"Aghbash","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines\u2013a review of the first decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib56","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00109-022-02199-y","article-title":"Current and future direction in treatment of HPV-related cervical disease","volume":"100","author":"Khairkhah","year":"2022","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119284_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2026.116193","article-title":"Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies","volume":"172","author":"Gholami","year":"2026","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2026.119284_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.virol.2021.07.005","article-title":"CRISPR\/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells","volume":"562","author":"Inturi","year":"2021","journal-title":"Virology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib59","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.ymthe.2019.08.012","article-title":"Systemic delivery of CRISPR\/Cas9 targeting HPV oncogenes is effective at eliminating established tumors","volume":"27","author":"Jubair","year":"2019","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tranon.2016.10.002","article-title":"vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6\/E7 CRISPR\/Cas9 on cervical cancer cell line","volume":"9","author":"Zhen","year":"2016","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12985-025-02783-x","article-title":"HPV-driven cancers: a looming threat and the potential of CRISPR\/Cas9 for targeted therapy","volume":"22","author":"Kermanshahi","year":"2025","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28144","article-title":"CRISPR\/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer","volume":"95","author":"Zhen","year":"2023","journal-title":"J. Med. Virol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119284_bib63","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.3390\/ijms26178685","article-title":"Disruption of Human Papillomavirus 16 E6\/E7 Genes Using All-in-One Adenovirus Vectors Expressing Eight Double-Nicking Guide RNAs","volume":"26","author":"Yamaji","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/v17010048","article-title":"Unveiling the molecular architecture of hbv spherical subviral particles: structure, symmetry, and lipid dynamics","volume":"17","author":"Garg","year":"2024","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib65","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12072-017-9829-7","article-title":"Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread","volume":"11","author":"Karayiannis","year":"2017","journal-title":"Hepatol. Int."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib66","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3390\/v16050724","article-title":"Hepatitis B virus infection: a mini review","volume":"16","author":"Asandem","year":"2024","journal-title":"Viruses"},{"issue":"11052","key":"10.1016\/j.biopha.2026.119284_bib67","first-page":"7","article-title":"The hepatitis B virus surface antigen: an evolved perfection and its unresolved mysteries","volume":"608","author":"Bell","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2026.119284_bib68","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"issue":"17","key":"10.1016\/j.biopha.2026.119284_bib69","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1128\/JVI.00873-12","article-title":"Entry of hepatitis B virus into immortalized human primary hepatocytes by clathrin-dependent endocytosis","volume":"86","author":"Huang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2026.119284_bib70","series-title":"Hepatitis B virus in human diseases","first-page":"1","article-title":"Hepatitis B virus virology and replication","author":"Hu","year":"2016"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib71","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/v16040609","article-title":"Mechanisms of hepatitis B virus cccDNA and minichromosome formation and HBV gene transcription","volume":"16","author":"G\u00f3mez-Moreno","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/microorganisms13010157","article-title":"From the Cytoplasm into the Nucleus\u2014Hepatitis B Virus Travel and Genome Repair","volume":"13","author":"Ringlander","year":"2025","journal-title":"Microorganisms"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib73","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40364-024-00611-y","article-title":"The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2026.119284_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.livres.2025.09.002","article-title":"Hepatitis B virus integration and hepatocarcinogenesis","author":"Ma","year":"2025","journal-title":"Liver Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib76","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12935-025-03849-0","article-title":"Perspectives on NcRNAs in HBV\/cccDNA-driven HCC progression","volume":"25","author":"Lin","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biopha.2026.119284_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1504736","article-title":"Cracking the code of HBV persistence: cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver Abscesses","volume":"12","author":"Saeed","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2026.119284_bib78","article-title":"Global mortality of chronic liver diseases attributable to Hepatitis B virus and Hepatitis C virus infections from 1990 to 2019 and projections to 2030","volume":"17","author":"Nguyen","year":"2024","journal-title":"J. Infect. Public Health"},{"issue":"04","key":"10.1016\/j.biopha.2026.119284_bib79","first-page":"145","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"3","author":"You","year":"2023","journal-title":"Infect. Dis. & Immun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/v14010004","article-title":"Recent progress and future prospective in HBV cure by CRISPR\/Cas","volume":"14","author":"Yang","year":"2021","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib81","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib82","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/liv.15805","article-title":"Targeted HBx gene editing by CRISPR\/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells","volume":"44","author":"Rawal","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.biopha.2026.119284_bib83","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","article-title":"Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9","volume":"31","author":"Kostyushev","year":"2023","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib84","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2024.05.025","article-title":"CRISPR-Cas13b-mediated suppression of HBV replication and protein expression","volume":"81","author":"McCoullough","year":"2024","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102112","article-title":"Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo","volume":"35","author":"Smekalova","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119284_bib86","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib87","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/hep4.1933","article-title":"Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing","volume":"6","author":"Zhou","year":"2022","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2026.119284_bib88","series-title":"Fundamentals of Cellular and Molecular Biology","first-page":"201","article-title":"Molecular Basis of Hepatitis C","author":"Rehman","year":"2024"},{"issue":"43","key":"10.1016\/j.biopha.2026.119284_bib89","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7137","key":"10.1016\/j.biopha.2026.119284_bib90","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature05654","article-title":"Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry","volume":"446","author":"Evans","year":"2007","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib91","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.01888-08","article-title":"Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection","volume":"83","author":"Liu","year":"2009","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119284_bib92","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1128\/JVI.00024-06","article-title":"Hepatitis C virus entry depends on clathrin-mediated endocytosis","volume":"80","author":"Blanchard","year":"2006","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib93","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4254\/wjh.v10.i2.186","article-title":"Hepatitis C virus: Morphogenesis, infection and therapy","volume":"10","author":"Morozov","year":"2018","journal-title":"World J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib94","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/v11010030","article-title":"Overview of HCV life cycle with a special focus on current and possible future antiviral targets","volume":"11","author":"Alazard-Dany","year":"2019","journal-title":"Viruses"},{"issue":"19","key":"10.1016\/j.biopha.2026.119284_bib95","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1128\/JVI.01370-13","article-title":"Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment","volume":"87","author":"Paul","year":"2013","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib96","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/v13030520","article-title":"Hepatitis C viral replication complex","volume":"13","author":"Li","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2024.101423","article-title":"Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals","volume":"67","author":"Fiehn","year":"2024","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib98","first-page":"1256","article-title":"Hepatitis virus-associated non-Hodgkin lymphoma: pathogenesis and treatment strategies","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib99","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.3390\/ijms21093057","article-title":"Hepatitis C virus and hepatocellular carcinoma: when the host loses its grip","volume":"21","author":"Goto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119284_bib100","unstructured":"Organization WH. Hepatitis C 2025 [Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c\u3009."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib101","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/liv.15150","article-title":"Road to elimination of HCV: Clinical challenges in HCV management","volume":"42","author":"Hayes","year":"2022","journal-title":"Liver Int."},{"issue":"29","key":"10.1016\/j.biopha.2026.119284_bib102","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3748\/wjg.v27.i29.4831","article-title":"Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease","volume":"27","author":"Khoo","year":"2021","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib104","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/jvh.13270","article-title":"Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents","volume":"27","author":"Liu","year":"2020","journal-title":"J. Viral Hepat."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib105","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/jcmm.15039","article-title":"The rapidly advancing Class 2 CRISPR-Cas technologies: a customizable toolbox for molecular manipulations","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/8819834","article-title":"Dual Detection of Hepatitis B and C Viruses Using CRISPR-Cas Systems and Lateral Flow Assay","volume":"2024","author":"Shahni","year":"2024","journal-title":"J. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12985-023-02048-5","article-title":"Potential of CRISPR\/Cas system as emerging tools in the detection of viral hepatitis infection","volume":"20","author":"Bahrulolum","year":"2023","journal-title":"Virol. J."},{"issue":"6366","key":"10.1016\/j.biopha.2026.119284_bib108","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119284_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111239","article-title":"CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy","volume":"136","author":"Ashraf","year":"2021","journal-title":"Biomed. & Pharmacother."},{"issue":"13","key":"10.1016\/j.biopha.2026.119284_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00280-17","article-title":"Attachment and postattachment receptors important for hepatitis C virus infection and cell-to-cell transmission","volume":"91","author":"Fan","year":"2017","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib111","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/ijms25010334","article-title":"CRISPR\/Cas9 as a new antiviral strategy for treating hepatitis viral infections","volume":"25","author":"Bartosh","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.biopha.2026.119284_bib112","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib113","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12985-023-02187-9","article-title":"Epstein-Barr virus infection: the micro and macro worlds","volume":"20","author":"Huang","year":"2023","journal-title":"Virol. J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib114","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/v15030714","article-title":"Epstein\u2013Barr virus history and pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.biopha.2026.119284_bib115","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.3390\/v14112372","article-title":"How EBV infects: the tropism and underlying molecular mechanism for viral infection","volume":"14","author":"Bu","year":"2022","journal-title":"Viruses"},{"issue":"22","key":"10.1016\/j.biopha.2026.119284_bib116","doi-asserted-by":"crossref","first-page":"11217","DOI":"10.1128\/JVI.01673-08","article-title":"Molecular basis of the interaction between complement receptor type 2 (CR2\/CD21) and Epstein-Barr virus glycoprotein gp350","volume":"82","author":"Young","year":"2008","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib117","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.immuni.2024.02.008","article-title":"Epstein-Barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to B cells","volume":"57","author":"Bu","year":"2024","journal-title":"Immunity"},{"issue":"23","key":"10.1016\/j.biopha.2026.119284_bib118","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.3390\/cancers14235780","article-title":"Functional implications of Epstein-Barr virus lytic genes in carcinogenesis","volume":"14","author":"Yap","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib119","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s10571-025-01622-5","article-title":"Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications","volume":"45","author":"Mohabbat","year":"2025","journal-title":"Cell. Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70501","article-title":"EBV latency programs: molecular and epigenetic regulation and its role in disease pathogenesis","volume":"97","author":"Lyu","year":"2025","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib121","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2020.12.022","article-title":"Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance","volume":"184","author":"Dheekollu","year":"2021","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib122","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3390\/v16040564","article-title":"Deciphering the role of Epstein\u2013Barr virus latent membrane protein 1 in immune modulation: A multifaced Signalling perspective","volume":"16","author":"\u0160imi\u010di\u0107","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib123","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.028","article-title":"EBV gene expression and regulation","author":"Young","year":"2007","journal-title":"Hum. herpesviruses Biol. Ther. Immunoprophyl."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib124","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3390\/biom11091380","article-title":"Stress-induced Epstein-Barr virus reactivation","volume":"11","author":"Sausen","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/rmv.1780","article-title":"Switching of EBV cycles between latent and lytic states","volume":"24","author":"Murata","year":"2014","journal-title":"Rev. Med. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib126","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/cancers16050991","article-title":"Epigenetic mechanisms in latent Epstein-Barr virus infection and associated cancers","volume":"16","author":"Torne","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119284_bib127","first-page":"4659","article-title":"Epstein\u2013Barr virus infection in cancer","author":"Mundo","year":"2023","journal-title":"MDPI"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein\u2013Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119284_bib129","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70603","article-title":"Harnessing Cellular Immunotherapy for EBV-associated malignancies: current advances and future directions","volume":"29","author":"Gao","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2026.119284_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199314","article-title":"Harnessing CRISPR technology for viral therapeutics and vaccines: from preclinical studies to clinical applications","volume":"341","author":"Zahedipour","year":"2024","journal-title":"Virus Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005701","article-title":"CRISPR\/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections","volume":"12","author":"van Diemen","year":"2016","journal-title":"PLoS Pathog."},{"issue":"36","key":"10.1016\/j.biopha.2026.119284_bib132","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.1410785111","article-title":"RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005701","article-title":"CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections","volume":"12","author":"van Diemen","year":"2016","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib134","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13027-019-0246-5","article-title":"CRISPR\/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth","volume":"14","author":"Huo","year":"2019","journal-title":"Infect. Agents Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib135","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/v17070899","article-title":"CRISPR\/Cas13-Mediated Inhibition of EBNA1 for Suppression of Epstein\u2013Barr Virus Transcripts and DNA Load in Nasopharyngeal Carcinoma Cells","volume":"17","author":"Lin","year":"2025","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib136","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00795-24","article-title":"Targeted eradication of EBV-positive cancer cells by CRISPR\/dCas9-mediated EBV reactivation in combination with ganciclovir","volume":"15","author":"Sugiokto","year":"2024","journal-title":"Mbio"},{"key":"10.1016\/j.biopha.2026.119284_bib137","unstructured":"Viruses ICoTo. Human herpesvirus 8 (HHV-8) \u2013 Kaposi\u2019s sarcoma\u2013associated herpesvirus 2023 [Available from: \u3008https:\/\/ictv.global\/report\/chapter\/orthoherpesviridae\/orthoherpesviridae\/rhadinovirus\u3009."},{"issue":"24","key":"10.1016\/j.biopha.2026.119284_bib138","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3390\/cancers13246208","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus, the etiological agent of all epidemiological forms of Kaposi\u2019s sarcoma","volume":"13","author":"Jary","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib139","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/viro.2001.0921","article-title":"Human herpesvirus 8 envelope-associated glycoprotein B interacts with heparan sulfate-like moieties","volume":"284","author":"Akula","year":"2001","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/JVI.01170-08","article-title":"Kaposi's sarcoma-associated herpesvirus gH\/gL: glycoprotein export and interaction with cellular receptors","volume":"83","author":"Hahn","year":"2009","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119284_bib141","doi-asserted-by":"crossref","first-page":"11583","DOI":"10.1128\/JVI.75.23.11583-11593.2001","article-title":"Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8. 1","volume":"75","author":"Birkmann","year":"2001","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119284_bib142","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/v11111073","article-title":"Towards understanding KSHV fusion and entry","volume":"11","author":"Dollery","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib143","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/v13010118","article-title":"Cellular receptors involved in KSHV infection","volume":"13","author":"van der Meulen","year":"2021","journal-title":"Viruses"},{"issue":"24","key":"10.1016\/j.biopha.2026.119284_bib144","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1111\/febs.16206","article-title":"Cancers associated with human gammaherpesviruses","volume":"289","author":"Wen","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2026.119284_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101336","article-title":"Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen: more than a key mediator of viral persistence","volume":"61","author":"Schulz","year":"2023","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib146","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12250-019-00114-3","article-title":"Towards better understanding of KSHV life cycle: from transcription and posttranscriptional regulations to pathogenesis","volume":"34","author":"Yan","year":"2019","journal-title":"Virol. Sin."},{"issue":"6764","key":"10.1016\/j.biopha.2026.119284_bib147","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/47266","article-title":"p53 inhibition by the LANA protein of KSHV protects against cell death","volume":"402","author":"Friborg","year":"1999","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib148","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/v17060835","article-title":"The Use of Intrinsic Disorder and Phosphorylation by Oncogenic Viral Proteins to Dysregulate the Host Cell Cycle Through Interaction with pRb","volume":"17","author":"Kast-Woelbern","year":"2025","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib149","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/v17020177","article-title":"Unraveling the Kaposi sarcoma-associated herpesvirus (KSHV) lifecycle: An overview of latency, lytic replication, and KSHV-associated diseases","volume":"17","author":"Losay","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.804215","article-title":"RTA and LANA competitively regulate let-7a\/RBPJ signal to control KSHV replication","volume":"12","author":"Di","year":"2022","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib151","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/v7010116","article-title":"Molecular biology of KSHV lytic reactivation","volume":"7","author":"Purushothaman","year":"2015","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib152","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1006\/viro.1998.9486","article-title":"Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein","volume":"252","author":"Lukac","year":"1998","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib153","doi-asserted-by":"crossref","first-page":"5556","DOI":"10.1128\/JVI.73.7.5556-5567.1999","article-title":"Identification of the immediate-early transcripts of Kaposi\u2019s sarcoma-associated herpesvirus","volume":"73","author":"Zhu","year":"1999","journal-title":"J. Virol."},{"issue":"5192","key":"10.1016\/j.biopha.2026.119284_bib154","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1126\/science.7997879","article-title":"Identification of herpesvirus-like DNA sequences in AIDS-sssociated kaposi's sarcoma","volume":"266","author":"Chang","year":"1994","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.NAJ.0000901848.07128.92","article-title":"CE: HIV-associated Kaposi sarcoma in the combination antiretroviral therapy era","volume":"122","author":"Mangusan","year":"2022","journal-title":"AJN Am. J. Nurs."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib156","first-page":"1013","article-title":"KSHV\/HHV8-mediated hematologic diseases","volume":"139","author":"Cesarman","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib157","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14787210.2023.2247161","article-title":"Clinical management of Kaposi sarcoma herpesvirus-associated diseases: an update on disease manifestations and treatment strategies","volume":"21","author":"Patel","year":"2023","journal-title":"Expert Rev. anti-Infect. Ther."},{"issue":"20","key":"10.1016\/j.biopha.2026.119284_bib158","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.3390\/ijms262010198","article-title":"Kaposi\u2019s Sarcoma: A Non-Communicable Outcome Mainly Prompted by Communicable Diseases in Sub-Saharan Africa","volume":"26","author":"Mamimandjiami","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib159","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.3390\/v13091797","article-title":"Recent advances in developing treatments of Kaposi\u2019s sarcoma herpesvirus-related diseases","volume":"13","author":"Naimo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101249","article-title":"Immunotherapy for KSHV-associated diseases","volume":"55","author":"Lurain","year":"2022","journal-title":"Curr. Opin. Virol."},{"issue":"18","key":"10.1016\/j.biopha.2026.119284_bib161","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/cancers16183194","article-title":"Localized Radiotherapy for Classic Kaposi\u2019s Sarcoma: An Analysis of Lesion Characteristics and Treatment Response","volume":"16","author":"Park","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib162","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/v12091034","article-title":"Regulation of KSHV latency and lytic reactivation","volume":"12","author":"Broussard","year":"2020","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib163","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02183-18","article-title":"Reduction of Kaposi\u2019s sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene","volume":"93","author":"Tso","year":"2019","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119284_bib164","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1002\/jmv.27046","article-title":"Reversible switching of primary cells between normal and malignant state by oncogenic virus KSHV and CRISPR\/Cas9-mediated targeting of a major viral latent protein","volume":"93","author":"Ju","year":"2021","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib165","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12985-021-01527-x","article-title":"Targeting the Kaposi\u2019s sarcoma-associated herpesvirus genome with the CRISPR-Cas9 platform in latently infected cells","volume":"18","author":"Haddad","year":"2021","journal-title":"Virol. J."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib166","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/v13050783","article-title":"Crispr interference efficiently silences latent and lytic viral genes in kaposi\u2019s sarcoma-associated herpesvirus-infected cells","volume":"13","author":"Brackett","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib167","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/v12090952","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus reactivation by targeting of a dcas9-based transcription activator to the orf50 promoter","volume":"12","author":"Elbasani","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2022.872599","article-title":"Molecular biology and diversification of human retroviruses","volume":"2","author":"Meissner","year":"2022","journal-title":"Front. Virol."},{"issue":"4572","key":"10.1016\/j.biopha.2026.119284_bib169","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1126\/science.6981847","article-title":"A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia","volume":"218","author":"Kalyanaraman","year":"1982","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-4690-2-30","article-title":"Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa","volume":"2","author":"Calattini","year":"2005","journal-title":"Retrovirology"},{"issue":"22","key":"10.1016\/j.biopha.2026.119284_bib171","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1073\/pnas.0501734102","article-title":"Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters","volume":"102","author":"Wolfe","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119284_bib172","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12985-021-01643-8","article-title":"Decoding pathogenesis factors involved in the progression of ATLL or HAM\/TSP after infection by HTLV-1 through a systems virology study","volume":"18","author":"Zarei Ghobadi","year":"2021","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib174","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1742-4690-7-99","article-title":"Current concepts regarding the HTLV-1 receptor complex","volume":"7","author":"Ghez","year":"2010","journal-title":"Retrovirology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib175","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3390\/v17050664","article-title":"Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges","volume":"17","author":"Branda","year":"2025","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib176","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3390\/v2092037","article-title":"Human T lymphotropic virus type 1 (HTLV-1): molecular biology and oncogenesis","volume":"2","author":"Kannian","year":"2010","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib177","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12977-020-0511-0","article-title":"HTLV-1 bZIP factor: the key viral gene for pathogenesis","volume":"17","author":"Matsuoka","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.biopha.2026.119284_bib178","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fmicb.2012.00406","article-title":"HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways","volume":"3","author":"Currer","year":"2012","journal-title":"Front. Microbiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib179","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pathogens9070543","article-title":"Mechanisms of oncogenesis by HTLV-1 Tax","volume":"9","author":"Mohanty","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.biopha.2026.119284_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2025.101480","article-title":"Human T-cell leukemia virus type I: modulation of viral gene expression and perturbation of host signaling pathways lead to persistent infection","volume":"73","author":"Shichijo","year":"2025","journal-title":"Curr. Opin. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib181","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/v8020034","article-title":"The role of HBZ in HTLV-1-induced oncogenesis","volume":"8","author":"Zhao","year":"2016","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib182","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12977-016-0249-x","article-title":"Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis","volume":"13","author":"Ma","year":"2016","journal-title":"Retrovirology"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib183","first-page":"1865","article-title":"HTLV-1 bZIP factor enhances TGF-\u03b2 signaling through p300 coactivator. Blood","volume":"118","author":"Zhao","year":"2011","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.biopha.2026.119284_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2021.101594","article-title":"Pathogenesis of HTLV-1 infection and progression biomarkers: An overview","volume":"25","author":"Brites","year":"2021","journal-title":"Braz. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011716","article-title":"The impact of HTLV-1 expression on the 3D structure and expression of host chromatin","volume":"20","author":"Yaguchi","year":"2024","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib186","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","article-title":"Human T cell leukemia virus type 1: persistence and pathogenesis","volume":"36","author":"Bangham","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119284_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107635","article-title":"Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)","volume":"148","author":"Weterings","year":"2025","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib188","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","article-title":"Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma","volume":"34","author":"Nakagawa","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib189","article-title":"A frequent PLC\u03b31 mutation in adult T-cell leukemia\/lymphoma determines functional properties of the malignant cells","volume":"1869","author":"Prawiro","year":"2023","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"10.1016\/j.biopha.2026.119284_bib190","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fmicb.2019.01302","article-title":"TRAF3 is required for NF-\u03baB pathway activation mediated by HTLV tax proteins","volume":"10","author":"Fochi","year":"2019","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib191","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003206","article-title":"The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology","volume":"9","author":"White","year":"2013","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib192","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1086\/596062","article-title":"Reactivation and mutation of newly discovered WU, KI, and Merkel cell carcinoma polyomaviruses in immunosuppressed individuals","volume":"199","author":"Sharp","year":"2009","journal-title":"J. Infect. Dis."},{"issue":"42","key":"10.1016\/j.biopha.2026.119284_bib193","doi-asserted-by":"crossref","first-page":"16272","DOI":"10.1073\/pnas.0806526105","article-title":"T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus","volume":"105","author":"Shuda","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib194","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3390\/cancers12071774","article-title":"Merkel cell polyomavirus and Merkel cell carcinoma","volume":"12","author":"Pietropaolo","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib195","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41419-025-07892-7","article-title":"The complex conundrum of Merkel cell carcinoma cellular ancestry","volume":"16","author":"Mazziotta","year":"2025","journal-title":"Cell Death & Dis."},{"issue":"21","key":"10.1016\/j.biopha.2026.119284_bib196","doi-asserted-by":"crossref","first-page":"11464","DOI":"10.3390\/ijms222111464","article-title":"Epigenetic dysregulations in merkel cell polyomavirus-driven merkel cell carcinoma","volume":"22","author":"Rotondo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.biopha.2026.119284_bib197","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1128\/JVI.02159-13","article-title":"Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling","volume":"87","author":"Griffiths","year":"2013","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/j.biopha.2026.119284_bib198","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1128\/JVI.01786-13","article-title":"The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression","volume":"87","author":"Shahzad","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2026.119284_bib199","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.739695","article-title":"From Merkel cell polyomavirus infection to Merkel cell carcinoma oncogenesis","volume":"12","author":"Krump","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119284_bib200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-virology-011720-121757","article-title":"Molecular mechanisms of merkel cell polyomavirus transformation and replication","volume":"7","author":"Liu","year":"2020","journal-title":"Annu. Rev. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib201","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/cancers15020444","article-title":"Merkel cell polyomavirus: infection, genome, transcripts and its role in development of Merkel cell carcinoma","volume":"15","author":"Houben","year":"2023","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.biopha.2026.119284_bib202","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.3390\/cancers14246176","article-title":"Epidemiology of Merkel cell polyomavirus infection and Merkel cell carcinoma","volume":"14","author":"Silling","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051180","article-title":"Merkel Cell Polyomavirus (MCPyV) and Its Possible Role in Head and Neck Cancers","volume":"13","author":"Passerini","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119284_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110186","article-title":"Current status of Merkel cell carcinoma: Epidemiology, pathogenesis and prognostic factors","volume":"599","author":"Li","year":"2024","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102977","article-title":"Merkel-cell carcinoma: ESMO\u2013EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"9","author":"Lugowska","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib206","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071614","article-title":"Merkel Cell Carcinoma: New Trends","volume":"13","author":"Zwijnenburg","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.biopha.2026.119284_bib207","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143506","article-title":"Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions","volume":"13","author":"Yusuf","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up","volume":"6","author":"D'Angelo","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib209","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.abd.2022.09.003","article-title":"Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease","volume":"98","author":"Siqueira","year":"2023","journal-title":"An. Bras. De. Dermatol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib210","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/biomedicines9070718","article-title":"Merkel cell carcinoma","volume":"9","author":"Dellambra","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib211","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/cancers11091260","article-title":"CRISPR\/Cas9 Editing of the Polyomavirus Tumor Antigens Inhibits Merkel Cell Carcinoma Growth In Vitro","volume":"11","author":"Temblador","year":"2019","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib212","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad333","article-title":"Benchmarking deep learning methods for predicting CRISPR\/Cas9 sgRNA on- and off-target activities","volume":"24","author":"Zhang","year":"2023","journal-title":"Brief. Bioinforma."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib213","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2580","article-title":"Merkel Cell Polyomavirus-Pathophysiology and Treatment in the Era of Gene-Targeted Therapies","volume":"34","author":"Chokwassanasakulkit","year":"2024","journal-title":"Rev. Med Virol."},{"key":"10.1016\/j.biopha.2026.119284_bib214","article-title":"CRISPR\/Cas9 targeting of MCPyV T antigen in Merkel tumors","volume":"2021","author":"Arora","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2026.119284_bib215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fmolb.2020.00010","article-title":"DETECTing Merkel Cell Polyomavirus in Merkel Tumors","volume":"7","author":"Arora","year":"2020","journal-title":"Front Mol. Biosci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib216","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/life11020100","article-title":"Structure, function, and interactions of the HIV-1 capsid protein","volume":"11","author":"Rossi","year":"2021","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib217","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/v15051030","article-title":"Cell-to-cell transmission of HIV-1 and HIV-2 from infected macrophages and dendritic cells to CD4+ T lymphocytes","volume":"15","author":"Calado","year":"2023","journal-title":"Viruses"},{"issue":"6686","key":"10.1016\/j.biopha.2026.119284_bib218","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib219","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0952-7915(97)80110-0","article-title":"Co-receptors for HIV-1 entry","volume":"9","author":"Moore","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2026.119284_bib220","series-title":"Molecular Medical Microbiology","first-page":"2229","article-title":"Human immunodeficiency virus","author":"Spearman","year":"2024"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12977-021-00566-0","article-title":"The HIV-1 capsid and reverse transcription","volume":"18","author":"Aiken","year":"2021","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib222","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/ncomms7660","article-title":"HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus","volume":"6","author":"Malikov","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib223","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cell.2021.01.025","article-title":"Cone-shaped HIV-1 capsids are transported through intact nuclear pores","volume":"184","author":"Zila","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.biopha.2026.119284_bib224","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1073\/pnas.1920631117","article-title":"HIV-1 uncoats in the nucleus near sites of integration","volume":"117","author":"Burdick","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2026.119284_bib225","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00018-018-2772-5","article-title":"Cellular and molecular mechanisms of HIV-1 integration targeting","volume":"75","author":"Engelman","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib226","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/v14051113","article-title":"Retroviral RNA processing","volume":"14","author":"Beemon","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib227","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/v16091423","article-title":"Exploring HIV-1 maturation: a new frontier in antiviral development","volume":"16","author":"McGraw","year":"2024","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib228","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cell.2013.09.044","article-title":"An integrated overview of HIV-1 latency","volume":"155","author":"Ruelas","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib229","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imr.12066","article-title":"CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure","volume":"254","author":"Okoye","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2026.119284_bib230","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet 2024 [Available from: \u3008https:\/\/www.unaids.org\/en\/resources\/fact-sheet\u3009."},{"key":"10.1016\/j.biopha.2026.119284_bib231","series-title":"Cancer and AIDS: Part II: Cancer Pathogenesis and Epidemiology","first-page":"115","article-title":"Risk factors for cancer","author":"Williams","year":"2018"},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib232","doi-asserted-by":"crossref","first-page":"e1525","DOI":"10.1016\/S2214-109X(25)00264-5","article-title":"Global burden of cancer attributable to HIV: a worldwide incidence analysis","volume":"13","author":"Huang","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2026.119284_bib233","series-title":"NanoBioMedicine","first-page":"167","article-title":"HIV: biology to treatment","author":"Verma","year":"2020"},{"issue":"24","key":"10.1016\/j.biopha.2026.119284_bib234","doi-asserted-by":"crossref","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119284_bib235","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COH.0000000000000688","article-title":"Eliminating HIV reservoirs for a cure: the issue is in the tissue","volume":"16","author":"Busman-Sahay","year":"2021","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib236","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pathogens14010015","article-title":"The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection","volume":"14","author":"Murzin","year":"2024","journal-title":"Pathogens"},{"issue":"21","key":"10.1016\/j.biopha.2026.119284_bib237","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2418467122","article-title":"BRD9 functions as an HIV-1 latency regulatory factor","volume":"122","author":"Luk","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib238","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic T cell\u2013resistant HIV reservoirs to elimination ex vivo","volume":"130","author":"Ren","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib239","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cblock-and-lock\u201d strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep."},{"issue":"504","key":"10.1016\/j.biopha.2026.119284_bib240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib241","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain\u2013modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib242","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib243","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10142-025-01613-1","article-title":"New hope and promise with CRISPR-Cas9 technology for the treatment of HIV","volume":"25","author":"Hassan","year":"2025","journal-title":"Funct. & Integr. Genom."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib244","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"3","author":"Ebina","year":"2013","journal-title":"Sci. Rep."},{"issue":"31","key":"10.1016\/j.biopha.2026.119284_bib245","doi-asserted-by":"crossref","first-page":"11461","DOI":"10.1073\/pnas.1405186111","article-title":"RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection","volume":"111","author":"Hu","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib246","article-title":"Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR\/Cas9 gene editing","volume":"6","author":"Kaminski","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.biopha.2026.119284_bib247","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/v13091850","article-title":"Efficient inhibition of HIV using CRISPR\/Cas13d nuclease system","volume":"13","author":"Nguyen","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119284_bib248","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2022.02.010","article-title":"A combinatorial CRISPR-Cas12a attack on HIV DNA","volume":"25","author":"Fan","year":"2022","journal-title":"Mol. Ther. Methods & Clin. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib249","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib250","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib251","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2017.032","article-title":"Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR\/Cas9 confers resistance to both X4-and R5-tropic human immunodeficiency virus type 1 infection","volume":"29","author":"Yu","year":"2018","journal-title":"Hum. gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib252","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymthe.2021.10.026","article-title":"Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing","volume":"30","author":"Knipping","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119284_bib253","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.omtm.2022.01.012","article-title":"CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice","volume":"24","author":"Li","year":"2022","journal-title":"Mol. Ther. Methods & Clin. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib254","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61626-x","article-title":"CRISPR\/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1","volume":"14","author":"Khamaikawin","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib255","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/life15020276","article-title":"Breaking barriers to an HIV-1 cure: innovations in gene editing, immune modulation, and reservoir eradication","volume":"15","author":"Borrajo","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.biopha.2026.119284_bib256","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119284_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.590989","article-title":"The use of CRISPR\/Cas9 as a tool to study human infectious viruses","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2026.119284_bib258","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2022.1050507","article-title":"CRISPR nuclease off-target activity and mitigation strategies","volume":"4","author":"Wienert","year":"2022","journal-title":"Front. Genome Ed."},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib259","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12539-018-0298-z","article-title":"Review of CRISPR\/Cas9 sgRNA design tools","volume":"10","author":"Cui","year":"2018","journal-title":"Interdiscip. Sci. Comput. Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-022-00384-4","article-title":"Elimination of Cas9-dependent off-targeting of adenine base editor by using TALE to separately guide deaminase to target sites","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Discov."},{"issue":"14","key":"10.1016\/j.biopha.2026.119284_bib261","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/cells11142186","article-title":"Recent advances in improving gene-editing specificity through CRISPR\u2013Cas9 nuclease engineering","volume":"11","author":"Huang","year":"2022","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2026.119284_bib262","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib263","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","article-title":"From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.biopha.2026.119284_bib264","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.3390\/cancers13112625","article-title":"Virus-driven carcinogenesis","volume":"13","author":"Hatano","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119284_bib265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.pmbts.2020.12.014","article-title":"Chen Y-C. CRISPR based genome editing and removal of human viruses","volume":"179","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119284_bib266","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119284_bib267","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib268","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-025-03433-8","article-title":"Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems","volume":"23","author":"Wang","year":"2025","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.biopha.2026.119284_bib269","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"issue":"48","key":"10.1016\/j.biopha.2026.119284_bib270","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303149","article-title":"Bioactivable STING Nanoagonists to Synergize NIR-II Mild Photothermal Therapy Primed Robust and Long-Term Anticancer Immunity","volume":"35","author":"Ma","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2026.119284_bib271","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1138596","article-title":"Immunogenicity of CRISPR therapeutics\u2014Critical considerations for clinical translation","volume":"11","author":"Ewaisha","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119284_bib272","article-title":"Exploring protein orthogonality in immune space: a case study with AAV and Cas9 orthologs","author":"Moreno","year":"2018","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.biopha.2026.119284_bib273","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.celrep.2016.03.042","article-title":"CRISPR\/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape","volume":"15","author":"Wang","year":"2016","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119284_bib274","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1089\/crispr.2022.0051","article-title":"Advances in CRISPR delivery methods: perspectives and challenges","volume":"5","author":"Demirci","year":"2022","journal-title":"CRISPR J."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib275","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.apsb.2024.04.033","article-title":"Triterpenoids-templated self-assembly nanosystem for biomimetic delivery of CRISPR\/Cas9 based on the synergy of TLR-2 and ICB to enhance HCC immunotherapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2026.119284_bib276","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41467-021-22295-w","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119284_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107689","article-title":"Inactivation of the key ORFs of HBV for antiviral therapy by non-cleavage base editing","author":"Qin","year":"2025","journal-title":"Microb. Pathog."},{"issue":"7","key":"10.1016\/j.biopha.2026.119284_bib278","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ymthe.2023.03.024","article-title":"CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi","volume":"31","author":"Bendixen","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119284_bib279","article-title":"Scientific advancements in gene therapies: opportunities for global regulatory convergence","author":"Olaghere","year":"2025","journal-title":"MDPI"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226003173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:53:30Z","timestamp":1779245610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226003173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":279,"alternative-id":["S0753332226003173"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119284","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting human oncogenic viruses with CRISPR\/Cas: New therapeutic opportunities and challenges","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119284"}}